Elizabeth (Liz) Tallett
Elizabeth (Liz) Tallett is a respected leader with more than 30 years of experience in the worldwide biopharmaceutical and consumer products industries. Her senior management experience includes President and Chief Executive Officer of Transcell Technologies Inc., President of Centocor Pharmaceuticals, member of the Parke-Davis Executive Committee, and Director of Worldwide Strategic Planning for Warner-Lambert Company. Born and educated in England, she graduated from Nottingham University with dual first class honours degrees in mathematics and economics. Currently, Liz is a Principal of Hunter Partners, LLC, a management consulting practice that provides strategic advice and interim management for early to mid-stage pharmaceutical, biotech and medical device companies. Liz is a member of the board of directors of Principal Financial Group, Inc., Varian, Inc., Coventry Health Care Inc., Meredith Corp. and IntegraMed America Inc. She is currently the Lead Director for both Principal and Coventry Health Care. She was a founding board member of the Biotechnology Council of New Jersey, and is a Trustee of Solebury School, PA.
Paul Blake, MB, F.R.C.P
Dr. Blake is the Chief Medical Officer and Senior Vice President of Clinical Research and Development of Aeterna Zentaris, Inc. Prior to that, he was Executive Vice President of Worldwide Medical and Regulatory Operations at Cephalon, Inc., Senior Vice President and Medical Director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals (now GSK) and worked for ICI Pharmaceuticals (now AstraZeneca) and G.D. Searle. He qualified in medicine from the Royal Free Hospital School of Medicine, Long University. He is a fellow of the Royal College of Physicians, the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and of the American College of Clinical Pharmacology. Currently, Dr. Blake sits on the Board of Memory Pharmacuetical, Inc. He has also been a Director of ViaCell, Inc., until its purchase by Perkin Elmer in 2007 and a Director of Protez Pharmaceuticals, Inc., bought by Novartis in 2008. He has also served as a member of the Inter-Company Collaboration for Aids Drug Development and as a trustee of the Childrens Health Fund.
Chris Blaxland
Chris Blaxland has over 30 years of experience in small and large companies, with hands-on experience in general management, product development, marketing and technical aspects of the industry as well as the operational issues of establishing new biopharmaceutical companies. His senior executive experience includes positions in early stage biopharmaceutical and device companies (Greenwich Pharmaceuticals, Cell Pathways, PTC Therapeutics), leading their corporate development to becoming established research and development organizations, and in the preparation for commercialization. In a career of over 20 years at GlaxoSmithKline (SmithKline Beecham and SK&F) his roles included worldwide responsibility for strategic development of a major portfolio as Vice President of Strategic Product Development. Chris had increasingly senior roles as Director of Sales and Marketing in Australia and in Korea, and was General Manager of SK&F’s business in The Netherlands. He also has experience in management of manufacturing and regulatory affairs. Chris graduated as a veterinarian and practiced that profession in Australia and the United Kingdom before joining the pharmaceutical industry. Currently, Chris is a Principal of Hunter Partners, LLC, established in 2002. Hunter Partners, LLC is a management consulting practice that provides strategic advice and interim management for early to mid-stage pharmaceutical, biotechnology and medical device companies.